To take an example, the epidermal growth factor receptor (EGFR) inhibitor erlotinib is successful in treating non-small cell lung cancer (NSCLC) but is less effective in treating SCLC [5]. The gene discussed is EGFR; the disease is small cell lung carcinoma.